Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: Results of the prospective multicenter LALA-94 study

Leukemia

Volumn 20, Issue 12, 2006, Pages 2155-2161

  Vey, N ^a   Thomas, X ^b   Picard, C ^c   Kovascovicz, T ^d   Charin, C ^b   Cayuela, J M ^e   Dombret, H ^e   Dastugue, N ^f   Huguet, F ^f   Bastard, C ^g   Stamatoulas, A ^g   Giollant, M ^h   Tournilhac, O ^h   Macintyre, E ⁱ   Buzyn, A ⁱ   Bories, D ^j   Kuentz, M ^j   Dreyfus, F ^k   Delannoy, A ^l   Raynaud, S ^m   Gratecos, N ^m   Bordessoule, D ⁿ   de Botton, S ⁿ   Preudhomme, C ⁿ   Reman, O ^o   Troussard, X ^o   Pigneux, A ^p   Bilhou, C ^p   Vernant, J P ^q   Boucheix, C ^r   Gabert, J ^c   more..

^a INSTITUT PAOLI CALMETTES   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c HÔPITAL NORD   (France)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e SAINT LOUIS HOSPITAL   (France)

^f CHU PURPAN   (France)

^g Centre Henry Bequerel   (France)

^h Hotel Dieu   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j HENRI MONDOR HOSPITAL   (France)

^k Hôpital Cochin ^*  (France)

^l Hospital de Jolimont   (Belgium)

^m CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁿ CENTRE HOSPITALIER   (France)

^o CAEN UNIVERSITY HOSPITAL   (France)

^p HAUT LÉVÊQUE HOSPITAL   (France)

^q PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^r INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; IDARUBICIN; MIXED LINEAGE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR E2A;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 19; CHROMOSOME TRANSLOCATION 4; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 33751246497     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404420     Document Type: Article

References (35)

1. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547-561.
2. Fiere D, Lepage E, Sebban C, Boucheix C, Gisselbrecht C, Vernant JP et al. Adult acute lymphoblastic leukemia: A multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1993; 11: 1990-2001.
3. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and leukemia group B study 8811. Blood 1995; 85: 2025-2037.
4. Gokbuget N, Hoelzer D, Arnold R, Bohme A, Bartram CR, Freund M et al. Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000; 14: 1307-1325, ix.
5. Hoelzer D, Thiel E, Loffler H, Buchner T, Ganser A, Heil G et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123-131.
6. Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Loffler H, Fonatsch C et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87: 495-508.
7. Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998; 92: 1898-1909.
8. Ribera JM, Ortega JJ, Oriol A, Granada I, Hernandez-Rivas JM, Parody R et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 2002; 87: 154-166.
9. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol 1997; 96: 601-610.
10. Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantravahi R, Block AW et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 1999; 93: 3983-3993.
11. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings outcome. Blood 1996; 87: 3135-3142.
12. Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia-results of the prospective multicenter LALA-94 trial. Blood 2002; 100: 2357-2366.
13. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965-1971.
14. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
15. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003; 98: 1337-1354.
16. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605-615.
17. Raimondi SC, Behm FG, Roberson PK, Williams DL, Pui CH, Crist WM et al. Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). J Clin Oncol 1990; 8: 1380-1388.
18. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075-4086.
19. Biondi A, Rambaldi A, Rossi V, Elia L, Caslini C, Basso G et al. Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. Blood 1993; 82: 2943-2947.
20. Hunger SP, Galili N, Carroll AJ, Crist WM, Link MP, Cleary ML. The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. Blood 1991; 77: 687-693.
21. Troussard X, Rimokh R, Valensi F, Leboeuf D, Fenneteau O, Guitard AM et al. Heterogeneity of t(1;19)(q23;p13) acute leukaemias. French Haematological Cytology Group. Br J Haematol 1995; 89: 516-526.
22. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
23. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'realtime' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003; 17: 2474-2486.
24. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
25. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
26. Hunger SP, Fall MZ, Camitta BM, Carroll AJ, Link MP, Lauer SJ et al. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): A Pediatric Oncology Group study. Blood 1998; 91: 1021-1028.
27. Izraeli S, Janssen JW, Haas OA, Harbott J, Brok-Simoni F, Walther JU et al. Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia: A comparison between cytogenetic and polymerase chain reaction analyses. Leukemia 1993; 7: 671-678.
28. Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti TJ et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): A Pediatric Oncology Group study. Blood 1990; 76: 117-122.
29. Foa R, Vitale A, Mancini M, Cuneo A, Mecucci C, Elia L et al. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: Biological and clinical features. Br J Haematol 2003; 120: 484-487.
30. Boissel N, Auclerc MF, Lheritier V, Perel Y, Thomas X, Leblanc T et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774-780.
31. Jeha S. Who should be treating adolescents and young adults with acute lymphoblastic leukaemia? Eur J Cancer 2003; 39: 2579-2583.
32. Johansson B, Moorman AV, Haas OA, Watmore AE, Cheung KL, Swanton S et al. Hematologic malignancies with t(4;11)(q21;q23)- a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants. Leukemia 1998; 12: 779-787.
33. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41-47.
34. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003; 102: 2746-2755.
35. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909-1915.